Australia markets closed

Cipla Limited (CIPLA.BO)

BSE - BSE Real-time price. Currency in INR
Add to watchlist
1,485.30-3.35 (-0.23%)
At close: 03:29PM IST
Full screen
Previous close1,488.65
Open1,480.35
Bid1,486.05 x 0
Ask1,486.20 x 0
Day's range1,479.85 - 1,493.95
52-week range940.80 - 1,519.00
Volume12,458
Avg. volume52,134
Market cap1.199T
Beta (5Y monthly)0.37
PE ratio (TTM)29.09
EPS (TTM)51.06
Earnings date24 July 2024 - 29 July 2024
Forward dividend & yield13.00 (0.87%)
Ex-dividend date01 Aug 2024
1y target estN/A
  • Zacks

    Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla

    Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.

  • Reuters

    UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says

    Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.

  • Reuters

    India pharma companies develop versions of Wegovy to get in on weight-loss windfall

    Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.